COMMUNIQUÉS West-GlobeNewswire

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss
11/12/2025
CRB-913 was safe and well-tolerated across all doses studied Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants A placebo-adjusted mean weight loss of 2.9% was observed [...]
Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications
11/12/2025
Mario Alberto Accardi PhD, President and founder of Centessa’s Orexin Program, appointed Chief Executive Officer and member of the Board of Directors BOSTON and LONDON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Centessa [...]
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis
11/12/2025
Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported by mid-2027 and [...]
BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025
11/12/2025
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late- [...]
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
11/12/2025
Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call today [...]
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio
11/12/2025
NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by [...]
InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China
11/12/2025
BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received [...]
Certara Appoints Jon Resnick as Chief Executive Officer
11/12/2025
Resnick brings decades of leadership experience in health sciences, business operations, strategy, innovation and commercial growth William Feehery to step down as CEO on December 31, 2025 Company reaffirms full year [...]
DISCO Pharmaceuticals Appoints Mark Manfredi as CEO and Announces Final Close of €36 Million Seed Financing
11/12/2025
Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCO Financing will support the development of novel surfaceome-targeted therapies for [...]
Eukarÿs Wins 2025 BioTools Innovator Grand Prize and Joins BARDA’s Elite VANGUARD Program
11/12/2025
Press Release Eukarÿs Wins 2025 BioTools Innovator Grand Prize and Joins BARDA’s Elite VANGUARD Program • Awarded the 2025 BioTools Innovator Grand Prize, receiving $250,000 • Chosen by BARDA as a critical enabling [...]
ITM to Present at the 44th Annual J.P. Morgan Healthcare Conference
11/12/2025
Garching / Munich, Germany, November 11, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that its Chief Executive Officer, Dr. Andrew Cavey and Chief [...]
Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease
11/12/2025
Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England’s National Health Service MOUNTAIN VIEW [...]
Bio Usawa Welcomes Global Health Strategist, Professor Prashant Yadav, as Chair of Its Global Access and Health Equity Advisory Board
11/12/2025
Strategic Appointment Aligns Business Growth with Mission to Deliver Equitable, Affordable Medicines SAN FRANCISCO and KIGALI, Rwanda, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bio Usawa Inc., a biotechnology company dedicated [...]
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
11/12/2025
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2025 – Genmab A/S (Nasdaq: GMAB) will hold its 2025 R&D Update and ASH Data Review Meeting [...]
Aukera Therapeutics Comes Out of Stealth
11/12/2025
David Urech to join the board BASEL, Switzerland, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aukera Therapeutics, a preclinical-stage biotech spin-off from the University of Basel is officially coming out of stealth as it enters [...]
Immunovant Announces Pricing of $550 Million Common Stock Financing
11/12/2025
Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal [...]
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
11/12/2025
Allschwil, Switzerland, December 11, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]
Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health
11/12/2025
Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline [...]
Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.
11/12/2025
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small [...]

Pages